Paula Dakin

1.4k total citations · 2 hit papers
34 papers, 970 citations indexed

About

Paula Dakin is a scholar working on Pulmonary and Respiratory Medicine, Rheumatology and Orthopedics and Sports Medicine. According to data from OpenAlex, Paula Dakin has authored 34 papers receiving a total of 970 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Pulmonary and Respiratory Medicine, 11 papers in Rheumatology and 9 papers in Orthopedics and Sports Medicine. Recurrent topics in Paula Dakin's work include Chronic Obstructive Pulmonary Disease (COPD) Research (10 papers), Bone health and osteoporosis research (8 papers) and Bone health and treatments (6 papers). Paula Dakin is often cited by papers focused on Chronic Obstructive Pulmonary Disease (COPD) Research (10 papers), Bone health and osteoporosis research (8 papers) and Bone health and treatments (6 papers). Paula Dakin collaborates with scholars based in United States, United Kingdom and Italy. Paula Dakin's co-authors include Jacques P. Brown, Henry G. Bone, Rachel B. Wagman, David L. Kendler, Christian Roux, Socrates E. Papapoulos, Nadia Daizadeh, Andrea Wang, Nicola Pannacciulli and Jorge Malouf and has published in prestigious journals such as SHILAP Revista de lepidopterología, American Journal of Respiratory and Critical Care Medicine and CHEST Journal.

In The Last Decade

Paula Dakin

31 papers receiving 955 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension

2017 662 citations Henry G. Bone, Rachel B. Wagman et al. The Lancet Diabetes & Endocrinology profile →
Dupilumab for chronic obstructive pulmonary disease with type 2 inflammation: a pooled analysis of two phase 3, randomised, double-blind, placebo-controlled trials

2025 18 citations Surya P. Bhatt, Klaus F. Rabe et al. The Lancet Respiratory Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Paula Dakin United States	9	613	561	378	165	142	34	970
S.H. Ralston United Kingdom	18	490 0.8×	350 0.6×	371 1.0×	105 0.6×	100 0.7×	35	1.0k
Charles-Joël Menkès France	12	351 0.6×	328 0.6×	181 0.5×	189 1.1×	123 0.9×	41	824
Stefan Kudlacek Austria	20	411 0.7×	320 0.6×	417 1.1×	62 0.4×	165 1.2×	49	1.0k
Ivo Valter United States	17	779 1.3×	685 1.2×	493 1.3×	134 0.8×	178 1.3×	28	1.4k
N. Zamberlan Italy	15	574 0.9×	539 1.0×	208 0.6×	67 0.4×	94 0.7×	23	998
D. Hosking United Kingdom	5	344 0.6×	311 0.6×	240 0.6×	105 0.6×	81 0.6×	10	734
S. Gonnelli Italy	13	414 0.7×	236 0.4×	206 0.5×	51 0.3×	112 0.8×	18	738
Christian Muschitz Austria	21	653 1.1×	299 0.5×	437 1.2×	184 1.1×	403 2.8×	72	1.3k
T Tomomitsu Japan	14	495 0.8×	268 0.5×	166 0.4×	55 0.3×	221 1.6×	53	789
Antonio Nino United States	12	388 0.6×	324 0.6×	320 0.8×	36 0.2×	224 1.6×	23	839

Countries citing papers authored by Paula Dakin

Since Specialization

Citations

This map shows the geographic impact of Paula Dakin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paula Dakin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paula Dakin more than expected).

Fields of papers citing papers by Paula Dakin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Paula Dakin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paula Dakin. The network helps show where Paula Dakin may publish in the future.

Co-authorship network of co-authors of Paula Dakin

This figure shows the co-authorship network connecting the top 25 collaborators of Paula Dakin. A scholar is included among the top collaborators of Paula Dakin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Paula Dakin. Paula Dakin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Christenson, Stephanie A., Nicola A. Hanania, Surya P. Bhatt, et al.. (2025). Type 2 inflammation biomarkers and their association with response to dupilumab in COPD (BOREAS): an analysis of a randomised, placebo-controlled, phase 3 trial. The Lancet Respiratory Medicine. 13(8). 687–697. 5 indexed citations

Bhatt, Surya P., Klaus F. Rabe, Nicola A. Hanania, et al.. (2025). Dupilumab Improves Health-Related Quality of Life and Respiratory Symptoms in Patients With COPD and Type 2 Inflammation: BOREAS and NOTUS. CHEST Journal. 168(1). 56–66. 1 indexed citations

Bourdin, Arnaud, Anand Shah, Caroline Baxter, et al.. (2025). Dupilumab Improves Lung Function, Asthma Control and Exacerbation Frequency in Allergic Bronchopulmonary Aspergillosis – Results from the Phase 2 LIBERTY ABPA AIRED Study. American Journal of Respiratory and Critical Care Medicine. 211(Supplement_1). A5230–A5230. 2 indexed citations

Bourdin, Arnaud, Jonathan Corren, Anand Shah, et al.. (2025). Dupilumab efficacy in patients with asthma and allergic bronchopulmonary aspergillosis (ABPA). OA2337–OA2337.

DiMartino, Stephen J., Haitao Gao, Guillermo J. Valenzuela, et al.. (2025). Efficacy and safety of fasinumab in an NSAID-controlled study in patients with pain due to osteoarthritis of the knee or hip. BMC Musculoskeletal Disorders. 26(1). 192–192. 1 indexed citations

Bafadhel, Mona, Stephanie A. Christenson, Claus Vogelmeier, et al.. (2024). IN PATIENTS WITH MODERATE OR SEVERE CHRONIC OBSTRUCTIVE PULMONARY DISEASE AND TYPE 2 INFLAMMATION, DUPILUMAB DOES NOT IMPACT BLOOD EOSINOPHIL LEVELS: PHASE 3 BOREAS TRIAL. CHEST Journal. 166(4). A4831–A4834. 1 indexed citations

DiMartino, Stephen J., Haitao Gao, Tuhina Neogi, et al.. (2024). Prevalence of preexisting articular bone pathology in patients with osteoarthritis screened for fasinumab clinical trials identified by X-ray or magnetic resonance imaging. Osteoarthritis and Cartilage. 32(12). 1601–1609. 1 indexed citations

DiMartino, Stephen J., Thomas J. Schnitzer, Haitao Gao, et al.. (2024). A phase III study to evaluate the long-term safety and efficacy of fasinumab in patients with pain due to osteoarthritis of the knee or hip. SHILAP Revista de lepidopterología. 6(4). 100533–100533. 2 indexed citations

Vogelmeier, Claus, Mona Bafadhel, Stephanie A. Christenson, et al.. (2024). DUPILUMAB IMPROVES HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE AND TYPE 2 INFLAMMATION: THE PHASE 3 NOTUS TRIAL. CHEST Journal. 166(4). A4814–A4818. 1 indexed citations

10.

Saini, Sarbjit S., Jonine L. Bernstein, Ana M. Giménez‐Arnau, et al.. (2024). Dupilumab significantly improves itch and hives in patients with chronic spontaneous urticaria (CUPID study C). Annals of Allergy Asthma & Immunology. 133(6). S2–S2. 3 indexed citations

11.

Vogelmeier, Claus, Mona Bafadhel, Stephanie A. Christenson, et al.. (2024). DUPILUMAB REDUCES EXACERBATIONS AND IMPROVES LUNG FUNCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE AND EMPHYSEMA. CHEST Journal. 166(4). A4809–A4813. 1 indexed citations

12.

Bhatt, Surya P., Klaus F. Rabe, Nicola A. Hanania, et al.. (2024). Dupilumab reduces exacerbations and improves lung function in patients with chronic obstructive pulmonary disease and emphysema: Phase 3 randomized trial (BOREAS). Respiratory Medicine. 236. 107846–107846.

13.

Dakin, Paula, Alan Kivitz, Joseph Gimbel, et al.. (2020). Efficacy and safety of fasinumab in patients with chronic low back pain: a phase II/III randomised clinical trial. Annals of the Rheumatic Diseases. 80(4). 509–517. 26 indexed citations

14.

Maloney, Jennifer, A. Kivitz, Thomas J. Schnitzer, et al.. (2017). Fasinumab in the treatment of hip and knee osteoarthritic pain: efficacy and safety in a 36-week randomized, double-blind placebo-controlled clinical trial. Osteoarthritis and Cartilage. 25. S56–S57. 3 indexed citations

15.

Adachi, Jonathan D., Henry G. Bone, Nadia Daizadeh, et al.. (2017). Influence of subject discontinuation on long-term nonvertebral fracture rate in the denosumab FREEDOM Extension study. BMC Musculoskeletal Disorders. 18(1). 174–174. 11 indexed citations

16.

Bone, Henry G., Rachel B. Wagman, Maria Luisa Brandi, et al.. (2017). 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. The Lancet Diabetes & Endocrinology. 5(7). 513–523. 662 indexed citations breakdown →

17.

Bone, Henry G., Maria Luisa Brandi, Jacques P. Brown, et al.. (2016). TEN YEARS OF DENOSUMAB (DMAB) TREATMENT IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS: RESULTS FROM THE FREEDOM EXTENSION TRIAL. Open Repository and Bibliography (University of Liège). 1 indexed citations

18.

Papapoulos, Socrates E., C. Roux, Paula Dakin, et al.. (2015). Denosumab treatment in postmenopausal women with osteoporosis for up to 9 years: results through year 6 of the freedom extension. Open Repository and Bibliography (University of Liège). 2 indexed citations

19.

Adachi, J.D., et al.. (2015). Evolution of subject characteristics in FREEDOM and its extension for up to 8 years. Australasian Journal on Ageing. 34. 64–65. 2 indexed citations

20.

Brown, Jacques P., Christian Roux, Pei‐Ran Ho, et al.. (2014). Denosumab significantly increases bone mineral density and reduces bone turnover compared with monthly oral ibandronate and risedronate in postmenopausal women who remained at higher risk for fracture despite previous suboptimal treatment with an oral bisphosphonate. Osteoporosis International. 25(7). 1953–61. 44 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact